Resamirigene bilparvovec
Resamirigene Bilparvovec is a gene therapy product developed for the treatment of Leber's congenital amaurosis (LCA), a rare genetic disorder affecting the retina at the back of the eye. It is the first gene therapy approved for a genetic disease in the United States by the Food and Drug Administration (FDA).
Overview[edit]
Resamirigene Bilparvovec, also known as Luxturna, is a novel gene therapy that introduces a normal copy of the RPE65 gene into retinal cells. The RPE65 gene is responsible for producing a protein that makes light perception possible in the eyes. Mutations in this gene cause LCA, leading to progressive vision loss and eventually blindness.
Mechanism of Action[edit]
Resamirigene Bilparvovec works by using a modified, harmless virus (Adeno-associated virus AAV) to deliver a normal copy of the RPE65 gene to retinal cells. The virus is injected directly into the retina where it enters the cells and delivers the gene. This allows the cells to produce the necessary protein for vision, restoring the patient's ability to respond to light.
Clinical Trials and Approval[edit]
The effectiveness of Resamirigene Bilparvovec was established in a clinical trial involving patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. The trial demonstrated significant improvement in the ability to navigate in low light, a common problem for people with LCA.
In December 2017, the FDA approved Resamirigene Bilparvovec, making it the first gene therapy for a genetic disease in the U.S. The European Medicines Agency (EMA) granted marketing authorization for the therapy in November 2018.
Side Effects[edit]
Like all medicines, Resamirigene Bilparvovec can cause side effects, although not everybody gets them. The most common side effects include eye redness, cataract, increased intraocular pressure, and retinal tear.
See Also[edit]
- Gene Therapy
- Leber's congenital amaurosis
- Food and Drug Administration
- Adeno-associated virus
- European Medicines Agency
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
